Literature DB >> 14662105

The cardioprotective effects of statins.

Jean Davignon1.   

Abstract

In addition to their lipid-modulating properties, statins have a large number of beneficial cardiovascular effects that have emerged over time and that were not anticipated during drug development. The lipid and nonlipid effects act in a concerted way to reduce the ischemic burden of the myocardium and to protect it against injury. By acting on the vessel wall, statins may prevent lesion initiation and repair injuries, enhance myocardial perfusion, slow lesion progression, and prevent coronary occlusion. They may also directly reduce myocardial damage, favor myocardial repair, and protect against immune injury. This review focuses on properties of statins that contribute to their cardioprotective effect. The first section includes information on modulation of vascular tone, endothelial permeability and function, inhibition of complement injury, curbing of foam cell formation, antioxidant and anti-inflammatory properties, and profibrinolytic and anticoagulant activities. The second section relates to reduction of myocardial necrosis, myocardial hypertrophy, blood pressure, and heart failure, as well as mobilization of endothelial progenitor cells for repair, angiogenic effects, and immunomodulation. In many instances, results of in vitro and animal studies have raised expectations and prompted studies in humans. Several clinical trials have confirmed these expectations and have strengthened the value of statins as valuable antiatherosclerotic and cardioprotective agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14662105     DOI: 10.1007/s11883-004-0113-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  105 in total

1.  Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.

Authors:  G Lowe; A Rumley; J Norrie; I Ford; J Shepherd; S Cobbe; P Macfarlane; C Packard
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

2.  Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction.

Authors:  Dirk H Walter; Stephan Fichtlscherer; Martina B Britten; Wolfgang Auch-Schwelk; Volker Schächinger; Andreas M Zeiher
Journal:  Am J Cardiol       Date:  2002-01-01       Impact factor: 2.778

3.  Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

Authors:  U Laufs; S Wassmann; S Hilgers; N Ribaudo; M Böhm; G Nickenig
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

4.  Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment.

Authors:  T Jared Bunch; Joseph B Muhlestein; Jeffrey L Anderson; Benjamin D Horne; Tami L Bair; Jeffrey D Jackson; Qunyu Li; Donald L Lappé
Journal:  Am J Cardiol       Date:  2002-08-01       Impact factor: 2.778

5.  Differential effect of simvastatin on activation of Rac(1) vs. activation of the heat shock protein 27-mediated pathway upon oxidative stress, in human smooth muscle cells.

Authors:  Pascale Nègre-Aminou; Rick E W van Leeuwen; G Christa F van Thiel; Paul van den IJssel; Wilfried W de Jong; Roy A Quinlan; Louis H Cohen
Journal:  Biochem Pharmacol       Date:  2002-11-15       Impact factor: 5.858

6.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

7.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

8.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival.

Authors:  D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

9.  Relation of inflammation and benefit of statins after percutaneous coronary interventions.

Authors:  Albert W Chan; Deepak L Bhatt; Derek P Chew; Joel Reginelli; Jakob P Schneider; Eric J Topol; Stephen G Ellis
Journal:  Circulation       Date:  2003-03-24       Impact factor: 29.690

10.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

View more
  7 in total

1.  Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2007

Review 2.  Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2016-12-12

3.  Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells.

Authors:  Brian D Lamon; Barbara D Summers; Antonio M Gotto; David P Hajjar
Journal:  Eur J Pharmacol       Date:  2009-01-14       Impact factor: 4.432

Review 4.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 5.  Ongoing clinical trials of the pleiotropic effects of statins.

Authors:  Jean Davignon; Lawrence A Leiter
Journal:  Vasc Health Risk Manag       Date:  2005

Review 6.  A novel therapeutic effect of statins on nephrogenic diabetes insipidus.

Authors:  Leonilde Bonfrate; Giuseppe Procino; David Q-H Wang; Maria Svelto; Piero Portincasa
Journal:  J Cell Mol Med       Date:  2015-01-16       Impact factor: 5.310

7.  Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.

Authors:  Agnieszka Łoboda; Józef Dulak
Journal:  Pharmacol Rep       Date:  2020-07-20       Impact factor: 3.024

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.